SCHEMBL8092924

SCHEMBL8092924

CN(C)c1cc(Nc2ccccc2)nc(N2CCN(c3cccc(OCc4ccccc4)c3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 8/20 0.46
GALR1 P47211 6/20 0.46
MAPT P10636 4/20 0.42
USP2 O75604 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
ESR2 Q92731 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
HPGD P15428 2/20 0.41
HTT P42858 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
F10 P00742 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.40
ALOX5 P09917 1/20 0.39
TSHR P16473 1/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8089157 0.95 GALR2 (0.46) GALR2GALR1MAPTUSP2MAPK1
SCHEMBL6790622 0.94 GALR2 (0.46) GALR2GALR1MAPTUSP2MAPK1
SCHEMBL8254144 0.92 JAK2 (0.46) GALR2GALR1MAPTUSP2MAPK1
SCHEMBL6790623 0.92 MAOB (0.42) GALR2GALR1MAPTUSP2MAPK1
SCHEMBL6352398 0.90 GALR1 (0.45) GALR2GALR1MAPK1HPGDHTT
SCHEMBL6356253 0.89 GALR2 (0.53) GALR2GALR1F10PIK3CA
SCHEMBL8254491 0.89 F10 (0.44) GALR2GALR1MAPTUSP2MAPK1
SCHEMBL6353168 0.89 GALR2 (0.55) GALR2GALR1LMNASMN1; SMN2PIK3CA
SCHEMBL6788494 0.88 KDM4E (0.48) GALR2GALR1MAPTKMT2AHPGD
SCHEMBL8094102 0.86 ALDH1A1 (0.53) GALR2GALR1MAPTMAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain GALR3, GALR2, GALR1 GALR2 2/4885GALR1 3/4885MAPT 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.